nach oben

Current Breast Cancer Reports

Erschienen in:

16.07.2019 | Translational Research (RL Aft, Section Editor)

How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma

verfasst von: Kimberly Dessources, Ana Paula Martins Sebastiao, Fresia Pareja, Britta Weigelt, Jorge S. Reis-Filho

Erschienen in: Current Breast Cancer Reports | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. Despite numerous studies investigating the progression from in situ to invasive disease, there is still controversy as to the mechanisms by which a DCIS comes to become an invasive cancer. Here, we reviewed the state-of-the-art of the pathologic and molecular characterization of DCIS.

Recent Findings

DCIS displays intra-lesion genetic heterogeneity. Single-cell sequencing studies have demonstrated that progression from DCIS to invasive breast cancer is a complex phenomenon, which can vary from lesion to lesion. While in some DCIS, multiple clones have the ability to invade, in others, clonal selection likely takes place.

Summary

The fact that DCIS displays intra-lesion genetic heterogeneity and that progression varies from patient to patient poses formidable challenges for the development of biomarkers to define the risk of progression to invasive breast cancer.

Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumors of the breast. 4th Edition ed. IARC Press; 2012.

Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10. https://doi.org/10.1093/jnci/djt067.CrossRefPubMedPubMedCentral

• Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol. 2012;227(1):42–52. https://doi.org/10.1002/path.3990. They demonstrate that some DCIS and invasive breast carcinomas are composed of mosaics of neoplastic cells that harbor genetic alterations in addition to the founder genetic events, and the selection of populations with specific genomic alterations takes place in the progression from DCIS to invasive breast cancer. CrossRefPubMedPubMedCentral

Cowell CF, Weigelt B, Sakr RA, Ng CK, Hicks J, King TA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol. 2013;7(5):859–69. https://doi.org/10.1016/j.molonc.2013.07.005.CrossRefPubMedPubMedCentral

•• Martelotto LG, Baslan T, Kendall J, Geyer FC, Burke KA, Spraggon L, et al. Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. Nat Med. 2017;23(3):376–85. https://doi.org/10.1038/nm.4279. Applying single-cell sequencing to FFPE tumor material, they studied the progression from in situ to invasive breast cancer, which revealed that DCIS display intra-tumor genetic heterogeneity at diagnosis and that these lesions may progress to invasive breast cancer through a variety of evolutionary processes.

Casasent AK, Edgerton M, Navin NE. Genome evolution in ductal carcinoma in situ: invasion of the clones. J Pathol. 2017;241(2):208–18. https://doi.org/10.1002/path.4840.CrossRefPubMed

•• Casasent AK, Schalck A, Gao R, Sei E, Long A, Pangburn W, et al. Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing. Cell. 2018;172(1–2):205–17.e12. https://doi.org/10.1016/j.cell.2017.12.007. The authors developed a spatially resolved single-cell genome sequencing method. Studying DCIS-IDC, genomic evolution was reported to occur in the DCIS, and invasion was found to entail the co-migration of multiple clones into the adjacent tissues.

Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, et al. National Institutes of Health state-of-the-science conference statement: diagnosis and Management of Ductal Carcinoma in Situ September 22-24, 2009. J Natl Cancer Inst. 2010;102(3):161–9. https://doi.org/10.1093/jnci/djp485.CrossRefPubMed

Wellings SR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst. 1973;50(5):1111–8.CrossRefPubMed

10.

Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol. 2015;28(5):662–9. https://doi.org/10.1038/modpathol.2014.141.CrossRefPubMed

11.

Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76(7):1197–200.CrossRefPubMed

12.

Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' health study. Cancer. 2005;103(9):1778–84. https://doi.org/10.1002/cncr.20979.CrossRefPubMed

13.

Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812–23. https://doi.org/10.1016/S0140-6736(11)61539-0.CrossRefPubMed

14.

Hanby AM. The pathology of breast cancer and the role of the histopathology laboratory. Clin Oncol (R Coll Radiol). 2005;17(4):234–9.CrossRef

15.

Maxwell AJ, Clements K, Hilton B, Dodwell DJ, Evans A, Kearins O, et al. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. Eur J Surg Oncol. 2018;44(4):429–35. https://doi.org/10.1016/j.ejso.2017.12.007.CrossRefPubMed

16.

Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006;19(5):617–21. https://doi.org/10.1038/modpathol.3800570.CrossRefPubMed

17.

Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer. 2008;98(1):137–42. https://doi.org/10.1038/sj.bjc.6604112.CrossRefPubMed

18.

Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008;10(4):R67. https://doi.org/10.1186/bcr2128.CrossRefPubMedPubMedCentral

19.

Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol. 2010;4(4):357–68. https://doi.org/10.1016/j.molonc.2010.06.007.CrossRefPubMedPubMedCentral

20.

Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer. 2011;104(1):120–7. https://doi.org/10.1038/sj.bjc.6606021.CrossRefPubMed

21.

Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17: intraductal carcinoma. Cancer. 1999;86(3):429–38.CrossRefPubMed

22.

Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and bowel project experience. Semin Oncol. 2001;28(4):400–18.CrossRefPubMed

23.

Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC breast Cancer cooperative group and EORTC radiotherapy group. J Clin Oncol. 2006;24(21):3381–7. https://doi.org/10.1200/JCO.2006.06.1366.CrossRefPubMed

24.

Han MS, Khan SA. Clinical trials for ductal carcinoma in situ of the breast. J Mammary Gland Biol Neoplasia. 2018;23:293–301. https://doi.org/10.1007/s10911-018-9413-3.CrossRefPubMed

25.

Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer. 2010;103(1):94–100. https://doi.org/10.1038/sj.bjc.6605718.CrossRefPubMedPubMedCentral

26.

Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and bowel project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000. https://doi.org/10.1016/S0140-6736(99)05036-9.CrossRefPubMed

27.

Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–73. https://doi.org/10.1200/JCO.2010.34.0141.CrossRefPubMedPubMedCentral

28.

Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2003;2(11):1113–20.PubMed

29.

Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, et al. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013;142(2):415–21. https://doi.org/10.1007/s10549-013-2755-z.CrossRefPubMedPubMedCentral

30.

Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the eastern cooperative oncology group. J Clin Oncol. 2009;27(32):5319–24. https://doi.org/10.1200/JCO.2009.21.8560.CrossRefPubMedPubMedCentral

31.

Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol. 2015;33(33):3938–44. https://doi.org/10.1200/JCO.2015.60.8588.CrossRefPubMedPubMedCentral

32.

Bremer T, Whitworth PW, Patel R, Savala J, Barry T, Lyle S, et al. A Biological Signature for Breast Ductal Carcinoma. Clin Cancer Res. 2018;24(23):5895–901. https://doi.org/10.1158/1078-0432.CCR-18-0842.CrossRefPubMed

33.

Wärnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol. 2014;32(32):3613–8. https://doi.org/10.1200/JCO.2014.56.2595.CrossRefPubMed

34.

Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(10):5974–9. https://doi.org/10.1073/pnas.0931261100.CrossRefPubMedPubMedCentral

35.

•• Doebar SC, Krol NM, van Marion R, Brouwer RWW, van Ijcken WFJ, Martens JM, et al. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing. Virchows Arch. 2018;474(2):247–51. https://doi.org/10.1007/s00428-018-2463-5. The authors found a high genomic concordance between synchronous DCIS and invasive breast cancers. The proportion of tumor cells harboring shared mutations between the DCIS and IDC was higher in the invasive component in a subset of patients. Their findings support the notion that progression of DCIS to invasive carcinoma could be driven by clonal selection.

36.

•• Pang JB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R, et al. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Mod Pathol. 2017;30(7):952–63. https://doi.org/10.1038/modpathol.2017.21. GATA3 mutations in DCIS were found to be a marker of less aggressive behavior. In contrast, TP53 mutations were associated with adverse tumor characteristics.

37.

Corzo C, Corominas JM, Tusquets I, Salido M, Bellet M, Fabregat X, et al. The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet. 2006;165(2):151–6. https://doi.org/10.1016/j.cancergencyto.2005.08.013.CrossRefPubMed

38.

Heselmeyer-Haddad K, Berroa Garcia LY, Bradley A, Ortiz-Melendez C, Lee WJ, Christensen R, et al. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Am J Pathol. 2012;181(5):1807–22. https://doi.org/10.1016/j.ajpath.2012.07.012.CrossRefPubMedPubMedCentral

39.

Pan A, Zhou Y, Mu K, Liu Y, Sun F, Li P, et al. Detection of gene copy number alterations in DCIS and invasive breast cancer by QM-FISH. Am J Transl Res. 2016;8(11):4994–5004.PubMedPubMedCentral

40.

• Sakr RA, Weigelt B, Chandarlapaty S, Andrade VP, Guerini-Rocco E, Giri D, et al. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Clin Cancer Res. 2014;20(9):2326–37. https://doi.org/10.1158/1078-0432.CCR-13-2267. The authors found genetic alterations affecting the PI3K pathway in a subset of pure DCIS and DCIS adjacent to invasive breast cancer. A receptor subtype-matched comparison of pure DCIS and DCIS adjacent to invasive breast cancer revealed that PIK3CA hotspot mutations and pAKT expression were significantly more prevalent in ER-positive /HER2-negative DCIS adjacent to invasive carcinoma. They concluded that molecular alterations affecting the PI3K pathway may play a role in the progression from high-grade DCIS to invasive breast cancer in a subset of ER-positive/ HER2-negative lesions.

41.

Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127–33. https://doi.org/10.1038/ng.2762.CrossRefPubMedPubMedCentral

42.

Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Jänicke F, et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2010;123(3):757–65. https://doi.org/10.1007/s10549-009-0675-8.CrossRefPubMed

43.

Rane SU, Mirza H, Grigoriadis A, Pinder SE. Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis. Breast Cancer Res Treat. 2015;153(1):101–21. https://doi.org/10.1007/s10549-015-3509-x.CrossRefPubMed

44.

Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512(7513):155–60. https://doi.org/10.1038/nature13600.CrossRefPubMedPubMedCentral

45.

Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, Faneyte IF, Nederlof PM, et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol. 2003;201(1):75–82. https://doi.org/10.1002/path.1385.CrossRefPubMed

46.

Jang M, Kim E, Choi Y, Lee H, Kim Y, Kim J, et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res. 2012;14(4):R115. https://doi.org/10.1186/bcr3239.CrossRefPubMedPubMedCentral

47.

Kitamura M, Nakayama T, Mukaisho KI, Mori T, Umeda T, Moritani S, et al. Progression potential of ductal carcinoma in situ assessed by genomic copy number profiling. Pathobiology. 2018;86:1–10. https://doi.org/10.1159/000492833.CrossRef

48.

Doebar SC, Sieuwerts AM, de Weerd V, Stoop H, Martens JWM, van Deurzen CHM. Gene expression differences between ductal carcinoma in situ with and without progression to invasive breast Cancer. Am J Pathol. 2017;187(7):1648–55. https://doi.org/10.1016/j.ajpath.2017.03.012.CrossRefPubMed

49.

Newburger DE, Kashef-Haghighi D, Weng Z, Salari R, Sweeney RT, Brunner AL, et al. Genome evolution during progression to breast cancer. Genome Res. 2013;23(7):1097–108. https://doi.org/10.1101/gr.151670.112.CrossRefPubMedPubMedCentral

50.

Lee JY, Schizas M, Geyer FC, Selenica P, Piscuoglio S, Sakr RA, et al. Lobular carcinomas. Clin Cancer Res. 2018;25:674–86. https://doi.org/10.1158/1078-0432.CCR-18-1103.CrossRefPubMedPubMedCentral

51.

Abba MC, Gong T, Lu Y, Lee J, Zhong Y, Lacunza E, et al. A molecular portrait of high-grade ductal carcinoma in situ. Cancer Res. 2015;75(18):3980–90. https://doi.org/10.1158/0008-5472.CAN-15-0506.CrossRefPubMedPubMedCentral

52.

Nelson AC, Machado HL, Schwertfeger KL. Breaking through to the other side: microenvironment contributions to DCIS initiation and progression. J Mammary Gland Biol Neoplasia. 2018;23(4):207–21. https://doi.org/10.1007/s10911-018-9409-z.CrossRefPubMedPubMedCentral

53.

Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–74. https://doi.org/10.1038/nrc745.CrossRefPubMed

54.

Hu M, Yao J, Cai L, Bachman KE, van den Brûle F, Velculescu V, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet. 2005;37(8):899–905. https://doi.org/10.1038/ng1596.CrossRefPubMed

55.

Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch. 2011;458(1):73–84. https://doi.org/10.1007/s00428-010-1013-6.CrossRefPubMed

56.

Teschendorff AE, Gao Y, Jones A, Ruebner M, Beckmann MW, Wachter DL, et al. DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nat Commun. 2016;7:10478. https://doi.org/10.1038/ncomms10478.CrossRefPubMedPubMedCentral

57.

Gudjonsson T, Rønnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J Cell Sci. 2002;115(Pt 1:39–50.PubMed

58.

Barsky SH, Karlin NJ. Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression. J Mammary Gland Biol Neoplasia. 2005;10(3):249–60. https://doi.org/10.1007/s10911-005-9585-5.CrossRefPubMed

59.

Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008;13(5):394–406. https://doi.org/10.1016/j.ccr.2008.03.007.CrossRefPubMedPubMedCentral

60.

Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57(2):171–92. https://doi.org/10.1111/j.1365-2559.2010.03568.x.CrossRefPubMed

61.

Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications. Am J Surg Pathol. 2009;33(2):227–32. https://doi.org/10.1097/PAS.0b013e318180431d.CrossRefPubMed

62.

Rakha EA, Miligy IM, Gorringe KL, Toss MS, Green AR, Fox SB, et al. Invasion in breast lesions: the role of the epithelial-stroma barrier. Histopathology. 2018;72(7):1075–83. https://doi.org/10.1111/his.13446.CrossRefPubMed

63.

Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6(1):17–32. https://doi.org/10.1016/j.ccr.2004.06.010.CrossRefPubMed

64.

Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–60. https://doi.org/10.1146/annurev.immunol.22.012703.104803.CrossRefPubMed

65.

Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, et al. Immune escape in breast Cancer during. Cancer Discov. 2017;7(10):1098–115. https://doi.org/10.1158/2159-8290.CD-17-0222.CrossRefPubMedPubMedCentral

66.

Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A. 2012;109(8):2802–7. https://doi.org/10.1073/pnas.1108781108.CrossRefPubMed

67.

Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, et al. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat. 2013;139(2):381–90. https://doi.org/10.1007/s10549-013-2556-4.CrossRefPubMed

Titel: How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma
verfasst von: Kimberly Dessources
Ana Paula Martins Sebastiao
Fresia Pareja
Britta Weigelt
Jorge S. Reis-Filho
Publikationsdatum: 16.07.2019
Verlag: Springer US
Erschienen in: Current Breast Cancer Reports / Ausgabe 3/2019
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-019-00318-2

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Oncoplastic Breast-Conserving Surgery in Low- and Middle-Income Countries: Training Surgeons and Bridging the Gap

Late Presentation of Breast Cancer in Lower- and Middle-Income Countries

Polygenic Risk Scores in Breast Cancer

Bridging the Gap in Training and Clinical Practice in Sub-Saharan Africa

Breast Cancer Management Among Refugees and Forcibly Displaced Populations: a Call to Action

Breast Atypia as a Biomarker of Risk

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie